Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.

Anderlini, Paolo; Benjamin, Robert S.; Wong, F.; Kantarjian, Hagop; Andreeff, M.; Kornblau, S.; O’Brien, Susan; Mackay, Bruce; Ewer, Michael S.; Pierce, Sherry

doi:10.1200/jco.1995.13.11.2827

Cited by 109 publications

(69 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These data indirectly confirm that IDA is less cardiotoxic than DNR, and, as suggested, it can be used up to a cumulative dose of 150 mg/m 2 in patients without cardiac dysfunction. 19,20 Moreover, patients randomized to maintenance therapy with 6-MP and MTX did not have better outcomes than those randomized to observation. Although WBC count greater than 3000/L and increasing age are well-known prognostic factors in APL, little is known about the influence of anthracycline monochemotherapy on EFS.…”

Section: Discussionmentioning

confidence: 98%

Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up

Avvisati

Petti

Lo‐Coco

et al. 2002

Blood

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up

Avvisati

Petti

Lo‐Coco

et al. 2002

Blood

View full text Add to dashboard Cite

show abstract

“…46 In a retrospective study, a cumulative dose of idarubicin at 150 mg/m 2 was estimated to be safe, while 290 mg/m 2 was considered probably safe. 48 The therapeutic index of idarubicin versus doxorubicin with regard to chronic cardiotoxicity is estimated to be 1.8-1.9. In study TPOG-AML-97A, patients generally received a cumulative dose of idarubicin 63 mg/m 2 and mitoxantrone dose of 80 mg/m 2 , which is equivalent to a dose of 340 mg/m 2 of doxorubicin.…”

Section: Discussionmentioning

confidence: 99%

Improved treatment results for childhood acute myeloid leukemia in Taiwan

et al. 2005

View full text Add to dashboard Cite

To improve treatment results for children with de novo acute myeloid leukemia (AML), we introduced a novel protocol, Taiwan Pediatric Oncology Group-AML-97A, for AML other than acute promyelocytic leukemia (APL), for which modified conventional protocols were used. From January 1, 1997, to December 31, 2002, 141 children younger than 17 years old with de novo AML were enrolled. In total, 117 patients with non-APL AML were treated with induction therapy of idarubicin and cytarabine (Ara-C), postremission therapy with high-dose Ara-C -containing regimens for four monthly courses, and moderatedose therapy with idarubicin and Ara-C for four monthly courses. The first 19 patients with APL were treated with alltrans retinoic acid, idarubicin and Ara-C, with the remaining five patients receiving all-trans retinoic acid and idarubicin, followed by maintenance therapy for 2 years. Stem cell transplantation was performed in 29 patients in first remission with a similar outcome as chemotherapy alone. The remission rate in the AML-97A study was 90%, the 5-year survival 5175.3% (s.e.) and the 5-year event-free survival 5074.8%; for APL, these were 100%, 8677.0, and 7579.8%. For the whole group, the 5-year survival was 5774.7% and the 5-year event-free survival 5474.4%. The AML-97A regimen was well tolerated.

show abstract

“…These upper limit cumulative doses were 150 mg/m 2 for idarubicin 9 and 160 mg/m 2 for mitoxantrone, 10 which was compared to a generally accepted safe upper limit, cumulative dose of doxorubicin of 450 mg/m 2 . Therefore, the actual cumulative dose of idarubicin was multiplied by 3.0, and that of mitoxantrone by 2.8, to obtain a doxorubicin equivalent anthracycline dose.…”

Section: Methodsmentioning

confidence: 99%

Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977–1997

Murdych

Weisdorf

2001

Bone Marrow Transplant

146

121

View full text Add to dashboard Cite

Summary:Cardiac complications may result from high-dose chemotherapy or irradiation administered during the conditioning phase of bone marrow and blood stem cell transplantation (BMT). To assess the frequency of clinically serious cardiac toxicity related to the acute phase of BMT, we retrospectively examined life-threatening or fatal cardiotoxicity identified using the complications records of our transplant center clinical database. All serious cardiac toxicity events within 100 days of BMT except those attributable to septic shock, pneumonitis or multi-organ failure were reviewed. Of 2821 BMT patients at the University of Minnesota between 1977 and 1997, 26 were identified as having suffered major or fatal (n = 13) cardiotoxicity (0.9%, 19 adults and seven children). Rapidly progressive heart failure resulted in death of 11 patients, one patient had fatal pericardial tamponade, and one had an acute ventricular fibrillation arrest. The remaining 13 patients (50%) had lifethreatening cardiotoxicity including four patients with pericardial tamponade and nine patients with cardiac arrhythmias. Overall, we observed that acute, major cardiotoxic events attributable to BMT are uncommon, occurring with a frequency of Ͻ1%. These data suggest that with appropriate pre-transplant clinical evaluation, high-dose cyclophosphamide and irradiation in the BMT preparative phase does not result in frequent, clinically relevant short-term cardiac toxicity. Bone Marrow Transplantation (2001) 28, 283-287.

show abstract

Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia.

Abstract: In this patient group, IDA-related cardiomyopathy was uncommon with cumulative IDA doses of up to 290 mg/m2. Asymptomatic LVEF decreases were more frequent, but their predictive value for the development of CHF is unclear.

Cited by 109 publications

References 13 publications

Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up

Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up

Improved treatment results for childhood acute myeloid leukemia in Taiwan

Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977–1997

Contact Info

Product

Resources

About